Publications - Mersana

Fleximer

Papisov MI, Hiller A, Yurkovetskiy A, Yin M, Barzana M, Hillier S, Fischman AJ. Biomacromolecules. 2005 Sep-Oct;6(5):2659-70.

Acyclic Polyacetals From Polysaccharides. [Please contact Mersana for a copy of this article]

Papisov MI. ACS Symposium Series, Vol.786 (Biopolymers from polysaccharides and agroproteins), 2001, pp. 301-314.

Theoretical considerations of RES-avoiding liposomes: Molecular mechanics and chemistry of liposome interactions.

Papisov MI. Adv Drug Deliv Rev. 1998 Jun 8;32(1-2):119-138.

Modeling in vivo transfer of long-circulating polymers (two classes of long circulating polymers and factors affecting their transfer in vivo). [Please contact Mersana for a copy of this article]

Papisov MI. Adv Drug Deliv Rev., Special issue on long circulating drugs and drug carriers, 1995, 16:127-137.

XMT-1001

Phase 1 study of XMT-1001, a novel water soluble camptothecin conjugate, given as an intravenous infusion once every three weeks to patients with advanced solid tumors.

Sausville EA, Garbo L, Weiss GJ, Shkolny D, Yurkovetskiy AV, Bethune C, Ramanathan RK, Fram RJ. Proceedings of AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. 2009; abstract B52.

XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer.

Yurkovetskiy AV, Fram RJ. Adv Drug Deliv Rev. 2009 Nov 12; 61(13): 1193-1202.

XMT-1001, A novel polymeric prodrug of camptothecin, is a potent inhibitor of LS174 and A2780 human tumor xenografts in a mouse model.

Yurkovetskiy AV, Papisov M, Fischman AJ, Hiller A, Yin M, Rolke J, Harrison SD, Napier C, Ball R, Sheridan K, Hollister B, Leone PB, Olson JA, Schwertschlag US. Proc Am Assoc Cancer Res. 2007; abstract 781.

Pharmacokinetics of a novel camptothecin conjugate (XMT-1001) in the rat and dog.

Bethune C, Teitelbaum P, Haas A, Felder L, Tollefson J, Rolke J, Petter R, Leone PB, Yurkovetskiy AV, Yin M, Olson JA, Schwertschlag US. Proc Am Assoc Cancer Res. 2007; abstract 4723.

Synthesis of a macromolecular camptothecin conjugate with dual phase drug release. Yurkovetskiy AV, Hiller A, Syed S, Yin M, Lu XM, Fischman AJ, Papisov MI. Mol Pharm. 2004 Sep-Oct;1(5):375-82.

XMT-1107

Anti-angiogenic and anti-tumor activity of XMT-1107, a fumagillol-derived polymer conjugate, and its in vivo release product XMT-1191.

Akullian LC, Stevenson CA, Yurkovetskiy AV, Benson JD, Fram RJ, Lowinger, TB. Proc Am Assoc Cancer Res. 2009; abstract 60.

Pharmacokinetics of the novel fumagillol conjugate XMT-1107 in the rat.

Yurkovetskiy A, Shkolny DL, Akullian LC, Yin M, Meyers LL, Fram RJ, Lowinger TB. Proc Am Assoc Cancer Res. 2009; abstract 1572.

Anti-angiogenic fumagillin-related polymeric pro-drugs exhibit anti-tumor activity in B16 murine melanoma and human tumor xenograft models.

Akullian AC, Kane J, Yurkovetskiy A, Yin M, Petter RC, Hammond CE, Stevenson CA, Adams R, Napier C, Fram RJ. Proc Am Assoc Cancer Res. 2008; abstract 2327.

Other

Fully degradable hydrophilic polyals for protein modification.

Yurkovetskiy A, Choi S, Hiller A, Yin M, McCusker C, Syed S, Fischman AJ, Papisov MI. Biomacromolecules. 2005 Sep-Oct;6(5):2648-58.

A systemic route for drug loading to lymphatic phagocytes.

Papisov MI, Yurkovetskiy A, Syed S, Koshkina N, Yin M, Hiller A, Fischman AJ. Mol Pharm. 2005 Jan-Feb;2(1):47-56.

Overview Publications and Published Abstracts		Share Publications and Published Abstracts Fleximer Semisynthetic hydrophilic polyals. Papisov MI, Hiller A, Yurkovetskiy A, Yin M, Barzana M, Hillier S, Fischman AJ. Biomacromolecules. 2005 Sep-Oct;6(5):2659-70. Acyclic Polyacetals From Polysaccharides. [Please contact Mersana for a copy of this article] Papisov MI. ACS Symposium Series, Vol.786 (Biopolymers from polysaccharides and agroproteins), 2001, pp. 301-314. Theoretical considerations of RES-avoiding liposomes: Molecular mechanics and chemistry of liposome interactions. Papisov MI. Adv Drug Deliv Rev. 1998 Jun 8;32(1-2):119-138. Modeling in vivo transfer of long-circulating polymers (two classes of long circulating polymers and factors affecting their transfer in vivo). [Please contact Mersana for a copy of this article] Papisov MI. Adv Drug Deliv Rev., Special issue on long circulating drugs and drug carriers, 1995, 16:127-137. XMT-1001 Phase 1 study of XMT-1001, a novel water soluble camptothecin conjugate, given as an intravenous infusion once every three weeks to patients with advanced solid tumors. Sausville EA, Garbo L, Weiss GJ, Shkolny D, Yurkovetskiy AV, Bethune C, Ramanathan RK, Fram RJ. Proceedings of AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. 2009; abstract B52. XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer. Yurkovetskiy AV, Fram RJ. Adv Drug Deliv Rev. 2009 Nov 12; 61(13): 1193-1202. XMT-1001, A novel polymeric prodrug of camptothecin, is a potent inhibitor of LS174 and A2780 human tumor xenografts in a mouse model. Yurkovetskiy AV, Papisov M, Fischman AJ, Hiller A, Yin M, Rolke J, Harrison SD, Napier C, Ball R, Sheridan K, Hollister B, Leone PB, Olson JA, Schwertschlag US. Proc Am Assoc Cancer Res. 2007; abstract 781. Pharmacokinetics of a novel camptothecin conjugate (XMT-1001) in the rat and dog. Bethune C, Teitelbaum P, Haas A, Felder L, Tollefson J, Rolke J, Petter R, Leone PB, Yurkovetskiy AV, Yin M, Olson JA, Schwertschlag US. Proc Am Assoc Cancer Res. 2007; abstract 4723. Synthesis of a macromolecular camptothecin conjugate with dual phase drug release. Yurkovetskiy AV, Hiller A, Syed S, Yin M, Lu XM, Fischman AJ, Papisov MI. Mol Pharm. 2004 Sep-Oct;1(5):375-82. XMT-1107 Anti-angiogenic and anti-tumor activity of XMT-1107, a fumagillol-derived polymer conjugate, and its in vivo release product XMT-1191. Akullian LC, Stevenson CA, Yurkovetskiy AV, Benson JD, Fram RJ, Lowinger, TB. Proc Am Assoc Cancer Res. 2009; abstract 60. Pharmacokinetics of the novel fumagillol conjugate XMT-1107 in the rat. Yurkovetskiy A, Shkolny DL, Akullian LC, Yin M, Meyers LL, Fram RJ, Lowinger TB. Proc Am Assoc Cancer Res. 2009; abstract 1572. Anti-angiogenic fumagillin-related polymeric pro-drugs exhibit anti-tumor activity in B16 murine melanoma and human tumor xenograft models. Akullian AC, Kane J, Yurkovetskiy A, Yin M, Petter RC, Hammond CE, Stevenson CA, Adams R, Napier C, Fram RJ. Proc Am Assoc Cancer Res. 2008; abstract 2327. Other Fully degradable hydrophilic polyals for protein modification. Yurkovetskiy A, Choi S, Hiller A, Yin M, McCusker C, Syed S, Fischman AJ, Papisov MI. Biomacromolecules. 2005 Sep-Oct;6(5):2648-58. A systemic route for drug loading to lymphatic phagocytes. Papisov MI, Yurkovetskiy A, Syed S, Koshkina N, Yin M, Hiller A, Fischman AJ. Mol Pharm. 2005 Jan-Feb;2(1):47-56.

Publications and Published Abstracts